• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
【24h】

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting

机译：自然疗法的门诊患者中用度洛西汀或选择性5-羟色胺再摄取抑制剂治疗的抑郁症患者的健康相关生活质量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico.Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 MDD patients without sexual dysfunction. QoL was measured using the EQ-5D instrument. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16), while pain severity was measured using the pain items of the Somatic Symptom Inventory. Regression analyses were performed to compare the levels of QoL between duloxetine-treated (n=556) and SSRI-treated (n=776) patients, adjusting for baseline patient characteristics.Results: These MDD patients, on average, had moderately impaired QoL at baseline, and the level of QoL impairment was similar between the duloxetine and SSRI groups (EQ-5D score of 0.46 [SD =0.32] in the former and 0.47 [SD =0.33] in the latter, P=0.066). Both descriptive and regression analyses confirmed QoL improvements in both groups during follow-up, but duloxetine-treated patients achieved higher QoL. At 24 weeks, the estimated mean EQ-5D score was 0.90 in the duloxetine cohort, which was statistically significantly higher than that of 0.83 in the SSRI cohort (P<0.001). Notably, pain severity at baseline was also statistically significantly associated with poorer QoL during follow-up (P<0.001). In addition, this association was observed in the subgroup of SSRI-treated patients (P<0.001), but not in that of duloxetine-treated patients (P=0.479).Conclusion: Depressed patients treated with duloxetine achieved higher QoL, compared to those treated with SSRIs, possibly in part due to its moderating effect on the link between pain and poorer QoL.
机译：目的：评估在自然主义临床环境中（主要在中部）接受度洛西汀或选择性5-羟色胺再摄取抑制剂（SSRI）单药治疗长达6个月的重度抑郁症（MDD）患者的生活质量（QoL）水平患者，方法：本事后分析的数据来自为期6个月的前瞻性观察性研究，涉及1,549名无性功能障碍的MDD患者。使用EQ-5D仪器测量QoL。使用临床总体严重程度印象和16项抑郁症状自我报告快速清单（QIDS-SR16）来测量抑郁严重程度，而使用躯体症状清单中的疼痛项目来测量疼痛严重程度。进行回归分析以比较度洛西汀治疗（n = 556）和SSRI治疗（n = 776）患者的QoL水平，并根据基线患者特征进行了调整。结果：这些MDD患者平均而言，其QoL在在基线水平上，度洛西汀组和SSRI组之间的​​QoL损伤水平相似（前者的EQ-5D得分为0.46 [SD = 0.32]，后者的EQ-5D得分为0.47 [SD = 0.33]，P = 0.066）。描述性分析和回归分析均证实随访期间两组患者的QoL均得到改善，但度洛西汀治疗的患者的QoL更高。在第24周时，度洛西汀队列的估计平均EQ-5D分数为0.90，在统计学上显着高于SSRI队列的0.83（P <0.001）。值得注意的是，基线时的疼痛严重程度在随访期间也与统计学上较差的QoL显着相关（P <0.001）。此外，在SSRI治疗的患者亚组中观察到这种关联（P <0.001），但在度洛西汀治疗的患者亚组中未观察到这一关联（P = 0.479）。结论：与那些相比，接受度洛西汀治疗的抑郁患者的QoL更高用SSRIs治疗，可能部分是由于其对疼痛和较差的生活质量之间的联系有调节作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号